2017
Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome
Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 520-526.e2. PMID: 28655598, DOI: 10.1016/j.clml.2017.05.017.Peer-Reviewed Original ResearchConceptsMF/SSOverall survivalSézary syndromeHazard ratioImproved survivalMycosis fungoidesPatient survivalHighest quintileLowest quintileTreatment volumeImproved overall survivalMultivariable Cox regressionNational Cancer DatabaseKaplan-Meier methodAnnual patient volumeNational database analysisLog-rank testContinuous variablesMedian followMultivariable analysisCox regressionOS survivalCancer DatabasePatientsPatient volume
2011
Polymorphisms in immune function genes and non-Hodgkin lymphoma survival
Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. Journal Of Cancer Survivorship 2011, 6: 102-114. PMID: 22113576, PMCID: PMC3326600, DOI: 10.1007/s11764-010-0164-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCase-Control StudiesConnecticutCytokinesDisease-Free SurvivalFemaleGene FrequencyGenotypeHumansKaplan-Meier EstimateLymphoma, Non-HodgkinMiddle AgedModels, GeneticPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsSocioeconomic FactorsSurvival AnalysisSurvivorsYoung AdultConceptsNon-Hodgkin lymphomaNHL survivalHazard ratioCytokine genesNon-Hodgkin lymphoma survivalCox proportional hazards modelIncident NHL casesConnecticut Tumor RegistryDisease-free survivalKaplan-Meier curvesRisk of deathProportional hazards modelCombination of polymorphismsImmune function genesIL6 genotypeNHL prognosisTumor RegistryHistologic typeTumor characteristicsDecreased riskSecondary cancersNHL casesTumor interactionCancer occurrenceLymphoma survival